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Does vascular surgery cost too much?
G. Patrick Clagett, MD, Dallas, TexIt has been traditional over the past few years to use the
Presidential Address to give an update on Society for Vas-
cular Surgery (SVS) activities – in other words, to provide a
“state of the union” address and to tell you what’s gone on
during my watch. I am going to depart from that tradition
for two reasons. The first is that there is a superb treatise on
the scope of SVS activities and programs published in the
December 2008 issue of the Journal of Vascular Surgery by
our past President, Wayne Johnston.1 I urge you to read
this. Wayne outlines SVS programs in the context of stra-
tegic initiatives that were determined by the SVS Board of
Directors last year. I think that you will be impressed with
the multitude of SVS activities that are designed to serve
you, the membership. Our councils and their committees
are bursting with activity and over 270 SVS members
volunteer their time in serving on these committees.
I would like to emphasize two themes of Wayne’s
report. The first is that the SVS is making continued efforts
to reach out to the entire vascular community, including
international members, vascular technologists, vascular
physicians’ assistants, nurses, and, most recently, podia-
trists. We want to become a diverse and comprehensive
organization that represents all in the vascular surgery
community. Second, the process for council and committee
appointments has been revamped to make this a democratic
process. When there are committee vacancies, we send out
RFAs asking for your interest in committee assignments,
and we appoint on the basis of expertise and availability, not
on “who you know.” In my opinion, this process has dramat-
ically strengthened the effectiveness of our SVS committees.
So, watch your e-mail for these requests.
The second reason for departing from the traditional
address is that I have become increasingly concerned about
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doi:10.1016/j.jvs.2009.06.063the cost of vascular intervention. I think that this is reaching
a crisis state that will have an impact on the way in which we
practice. While I am concerned that vascular surgery may
cost too much, let me be clear in stating unequivocally that
vascular surgeons are the best bargain available when it
comes to treating vascular disease. That is because we
practice all modalities including medical, endoluminal, and
open surgical treatment of vascular disorders. Unlike oth-
ers, we are not wed to a single approach in treating our
patients. This makes vascular surgeons uniquely qualified to
determine what are the most effective and the least expen-
sive treatments available. Furthermore, it is better that we
make these determinations rather than having a govern-
mental agency or private insurer determine or dictate this
for us.
There are several looming, external threats driving
health care cost concerns. Our economy is in bad shape, we
are in a recession, and the federal deficit is ever increasing.
Estimates from the Congressional Budget Office project
the federal deficit to exceed two trillion dollars for 2009. If
you go online to the National Debt Clock, the estimate is
over 10 trillion.2
The real problem is that health care costs are sky-
rocketing and are a major factor in driving the national
debt.3 Total US health care spending is expected to double
to 4.3 trillion dollars by 2017 (Fig 1). Per capita spending
will increase from approximately 4000 to 13,000 dollars
per person per year over the next decade (Fig 2).
Federal spending for health care, which includes Medi-
care and Medicaid, is approximately 50% of all health
expenditures. Federal funding will also double from 800
billion to a little less than 2 trillion dollars in the next
decade. By 2017, Medicare spending is expected to rise to
884 billion dollars and this will be one fifth of all national
health care spending.3
It is hard to “wrap one’s head” around these numbers
and it is helpful to look at health care expenditures as a
percent of the gross domestic product or the total wealth of
our national economy. This is a complicated graph from an
influential article that appeared in Health Affairs in 20083
(Fig 3). The solid blue line represents the rate of growth in
national health care spending. This remains relatively stable
at roughly 6% per year. The red line represents the GDP
growth rate that has “taken a hit,” with a drop in 2007. The
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and this is expected to rise to about 20% in the next decade.
However, I think that these are underestimates because this
research was published in 2008, before our economy
tanked. Because the red line has decreased even more than
shown in the graph, the real percentage of health care
spending expressed as a percent of GDP may be much
higher. These levels of health care spending are simply not
sustainable.
Health care costs are eating up a huge proportion of the
federal budget. By 2018, Medicare and federal Medicaid costs
will consume one third of federal spending (Fig 4). Along with
Social Security, these federal expenditures will, by necessity,
Fig 1. Projected total national health expen
Fig 2. Per capita spending on heareduce funding for other prominent, federal entitlement pro-grams. Because entitlement programs have strong grassroots
support and congressional advocates, it is predictable that the
“entitlement squeeze” will become very political.
It is commonly thought that the arrival of baby
boomers into the Medicare beneficiary pool will drive a lot
of these increasing costs. To some extent that is true, but
this is only a modest fraction of projected overall health
costs.4 Of course, this fraction is located squarely in the
Medicare pool of patients, and the increase there will have
a major impact on future CMS budgets.3
As for total health care costs, the major factors driving
up the costs are known as “utilization” and “medical pr-
ices”3 as shown in the red and blue portions of the bars on
es to 2017. Data from Keehan et al, 2008.3
re. Data from Keehan et al, 2008.3this graph (Fig 5). Loosely translated, these costs have to do
ta fro
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 5 Clagett 1213with the way that physicians practice, how they charge, how
frequently they admit patients to hospitals, and how they
prescribe medicines and use expensive medical devices.
These areas will be major targets of health care policy
reformers.
There is huge variation in health care spending among
countries in the civilized world and the United States
Fig 3. US health expenditures as a percentage of the gr
annual growth in health expenditures (solid blue line) vs t
Keehan et al, 2008.3
Fig 4. Health care spending as a proportion of the fe
comprise approximately one third of the US budget. Daspends more than any other nation.5 Unfortunately, thisdoes not necessarily translate into better health outcomes.
This graph plots per capita spending vs life expectancy (Fig 6).
The United States leads the pack in terms of health care
spending but enjoys an average life expectancy equivalent
to Cuba, which spends a fraction as much on health care.
Looking within our own borders, there is huge regional
variation in health care spending in the United States.
mestic product (GDP) (light blue bars) and the average
erage annual GDP growth (solid red line). Adapted from
budget. In 2017, health care spending is projected to
m the Congressional Budget Office.oss do
he avderalThese are data from the Dartmouth Atlas of Health Care
al pe
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care spending across all states for patients with nine chron-
ically ill conditions, one of which is peripheral vascular
disease (Fig 7). The data are adjusted for age, gender, race,
illness severity, and other factors that might influence
health care utilization. The deep blue and light blue states
such as California, New York, and Texas, my own state, are
above average and relatively expensive for Medicare com-
pared with grey and green states such as Oklahoma and
Iowa.
Do higher spending levels result in better outcomes?
The resounding answer is no. In numerous studies, Dart-
Fig 5. Utilization (blue) and medical prices (red) domin
physicians’ practice patterns and their prescription of dr
2008.3
Fig 6. Life expectancy vs nationmouth health researchers have documented a troublingparadox; higher spending is actually associated with lower
quality of care and slightly worse outcomes.6-8 How can
this be? This graph plots the number of cardiologists per
100,000 population on the x-axis vs number of visits to
cardiologists on the y-axis (Fig 8). More cardiologists beget
more visits and referrals with more testing and interven-
tions that may not be helpful, and ultimately may be
harmful.
In our own specialty, this map shows the rate of aortic
aneurysm repair among different regions9 (Fig 9). There
are some aneurysm “hot spots” around the country, but
there are no known differences in the incidence of aortic
e growth in health care spending. These costs deal with
nd use of medical devices. Adapted from Keehan et al,
r capita spending on health care.ate th
ugs aaneurysms among these regions, and there are no decreased
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rate of death from aneurysm is the same, or even slightly
higher, than in regions with a comparatively low rate of
aneurysm repair. This may simply be due to a higher rate of
intervention with attendant morbidity and mortality.
These and other variations in CMS expenditures with no
improvement in outcomes and, possibly, worse out-
comes, are raising tremendous concern among federal
health policy makers.10
Our new administration has promised health care re-
Fig 7. Ratio of state to the US average of total Med
peripheral arterial disease) adjusted for age, illness severit
Wennberg et al, 2008.6
Fig 8. The correlation of the number of cardiologists per
100,000 population vs visits to cardiologists among Medicare
enrollees, from Wennberg et al, 2008.6form as a centerpiece among their ambitious initiatives (Fig10). In addition to health care costs, the President has
promised to take on the problem of the 47 million US
citizens who are uninsured or under-insured and lack access
to basic health care. Thus, change is truly on the way,
although we do not yet have a clear idea what that change
will be. However, rest assured that health care cost contain-
ment is a major component.
Comparative effectiveness research has been a buzz
word among health policy wonks in Washington for the
past 5 years or so,11 and this has developed major traction
in the Obama administration. Comparative effectiveness
research simply compares two treatments with the goal of
determining which is most effective.11,12 One may com-
pare medical treatments, medical vs surgical or other inter-
ventional treatments, surgical vs catheter-based interven-
tions, or even diagnostic modalities. As many of you know,
a significant “chunk” of money, or 1.1 billion dollars from
President Obama’s multibillion dollar Economic Stimulus
Package, is going to the NIH, the Agency for Healthcare
Research and Quality, or AHRQ, and the Department of
Health and Human Services specifically for comparative
effectiveness research. There is even talk of a Comparative
Effectiveness Research Institute with legislation introduced
by Senator Baucus last year.
When I first heard of comparative effectiveness re-
search, my first thought was that this is “rediscovering the
wheel”. We have been doing this for years: CREST,
NASCET, ACAS, and OVER are just a few examples of
trials in the vascular community that are basic “comparative
spending for patients with chronic diseases (including
other factors that influence health care utilization, fromicare
y, andeffectiveness research.” But what may be different in these
rep
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added feature of cost effectiveness analysis.12,13
There are those who argue that comparative effective-
ness research and cost-effectiveness analyses are two sepa-
rate and distinct disciplines. However, I think that the two
are inextricably bound. For example, if one compares two
treatments and finds that treatment A is only modestly
better than treatment B but costs ten times more, it would
seem reasonable to use treatment B for most patients.
However, if treatment A is vastly more superior to treat-
ment B, one may be willing to incur the added expense. So,
whether explicitly stated or not, comparative effectiveness
Fig 9. Regional variation in the rate of aortic aneurysm
Fig 10. Cartoon from the Ft Worth Star Tribune, 2009.research has clear economic implications. One of the mainreasons the federal government is promoting comparative
effectiveness research is the belief that it would reduce
variation in practice and, thereby, save money.
Research on comparative effectiveness has been inte-
grated into health care systems in other developed coun-
tries including Australia, Canada, Britain, France, and Ger-
many. Perhaps the best known is Britain’s National
Institute for Health and Clinical Excellence that goes by
the ironic acronym of “NICE.” NICE is an independent
government-funded organization that advises the British
National Health Service. It does not sponsor clinical trials
or other forms of primary data collection. Instead, it funds
meta-analyses of existing research and combines this with
cost-effectiveness analyses.
Since its inception in 1999, decisions from NICE have
generated a great deal of controversy.14 Of the 159 deci-
sions handed down by NICE up to 2008, approximately
one third have been appealed and a little less than half of
these appeals have been upheld. NICE has been variously
viewed as a heartless, governmental rationing agency or an
honest attempt to prioritize health care with the goal of
providing the most effective treatments for greatest num-
ber of British citizens at the lowest cost.
In February of this year, NICE came out with endovas-
cular aneurysm repair (EVAR) recommendations.15 It is
notable and laudable that NICE consulted with prominent
British vascular surgeons in their deliberations. As I inter-
pret this document, EVAR is recommended for patients
who are able to undergo open surgery and is not recom-
mended for “unfit” patients and those with ruptured aneu-
air, from Dartmouth-CMS-FDA Collaborative 2006.9rysms. Thus, these recommendations roughly parallel the
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Many of us in the United States would take exception to
these recommendations and would even go as far to say that
EVAR has its greatest benefit in patients who cannot toler-
ate open surgery and those with ruptured aneurysms.
Many are concerned that a similar US Comparative
Effectiveness Research Institute would mandate treatment
decisions and thereby reduce physicians’ autonomy.16,17 At
its worst, this is a “one size fits all” mentality that devalues
treatment decisions for unusual or special circumstances in
which a treatment might be successful even if it is outside of
“official guidelines.” The proponents of federal compara-
tive effectiveness research point out that the process will be
transparent, scholarly, and persuasive; will involve all stake-
holders; and will be designed to promote best practices by
gaining the respect of the medical community. In other
words, “buy-in” from practicing physicians is necessary for
the success of this approach.
However, in one document prepared by the Congres-
sional Budget Office, the author states, “To . . . reduce
health care spending in a meaningful way, the results of
comparative effectiveness analyses would . . . have to be
used in ways that changed the behavior of doctors . . . For
example, the higher value care identified by comparative
effectiveness research could be promoted . . . through fi-
nancial incentives – that is, payments to doctors . . .”.11 I
do not know about you, but this sounds to me like coercion
akin to “pay for performance.”
What is the role of the SVS in all of this? Well, we have
some of the tools to carry out comparative effectiveness
research. I say some because we are not in the position to
sponsor major, randomized clinical trials. However, we
have Practice Guidelines and Reporting Standards. Some
are published and others are in the pipeline to be published
in the Journal of Vascular Surgery. These are important
because they provide a framework based on careful, system-
atic and scholarly analyses that promote best practices. We
also have a growing Vascular Registry developed by the SVS
Outcomes Committee.
The SVS Carotid Registry has been eminently success-
ful and presented an important paper at our annual meeting
last year.18 This, in essence, is a report on comparative
effectiveness that compares carotid endarterectomy to ca-
rotid angioplasty/stenting. The Outcomes Committee has
also partnered with the New England Research Institute in
responding to an NIH Challenge Grant on Comparative
Effectiveness. The plan is to use SVS carotid registry data in
comparing medical vs interventional treatment, including
CAS and CEA, in the treatment of asymptomatic carotid
stenosis.
The Outcomes Committee also has plans to expand the
registry to include lower extremity interventions for critical
limb ischemia, thoracic dissections and other catastrophic
thoracic aortic problems, and, possibly, angioaccess. Pro-
spective registry data are key ingredients in analyzing out-
comes as well as costs. I urge you to consider joining SVS
Registry modules as they become available.Not only do we have the tools, we have the brain
power, talent, and drive to carry out this research. The
Clinical Practice Council has developed a Comparative
Effectiveness Task Force. They have already produced a
“white paper” or position statement that spells out our
plans for comparative effectiveness research that will in-
clude cost efficacy analyses.19 One of their first undertak-
ings will be a systematic review of treatments for intermit-
tent claudication that will focus on outcomes, durability,
quality of life, and costs. Medical or exercise therapy com-
pared with intervention will be the main topic. There are at
least three, recent randomized on this topic with conflicting
conclusions.20-22 These and other reports will comprise a
data base for a meta-analysis. A recent article from the New
York Times has already mentioned this as a target for
federal comparative effectiveness research stating, “How do
drugs and watchful waiting compare with surgery as a
treatment for leg pain that results from blockage of the
arteries in the lower legs?”23
There are many other areas that we can assess. For
example, is EVAR really the best treatment for a relatively
healthy person less than 65 years old who may have ex-
pected longevity of 20 years or more? Existing data would
suggest that EVAR is more expensive, is associated with
many more re-interventions, has inferior quality of life, has
no survival advantage in the long-term and may, in fact,
have poorer long-term survival.24
Other areas in vascular disease treatment ripe for com-
parative effectiveness research include “endo first” vs distal
bypass for critical limb ischemia; medical vs interventional
treatment for asymptomatic carotid disease; angioplasty vs
bypass for superficial femoral artery disease; IVC filters vs
pharmaco-mechanical prophylaxis for patients at high risk
for venous thromboembolism, and many others.
Why should the Society for Vascular Surgery take on
comparative effectiveness research? First, this would be
looked on favorably by government agencies such as CMS
and, if properly done, might be accepted without further
interference. This is a polite way of saying that it is far better
that we do it ourselves instead of AHRQ or some other
federal agency doing it for us. Second, as mentioned earlier,
of all specialty groups treating patients with vascular dis-
ease, we are the most unbiased because we practice all
modalities; that is, we are not wed to one approach. Thus,
we are best positioned of all to do this. Third, we have the
expertise and the will to carry out high quality comparative
effectiveness research.
Finally, these mandates are clearly spelled out in our
Mission Statement, to: “Clearly define the role of surgery,
endovascular surgery and medical treatment and preven-
tion of vascular disease” and to “Address social, economic,
ethical, and legal issues that relate to vascular surgery.”
INTEGRITY is our middle name. This is the right thing to
do for our membership, for our patients, and for the public.
In a memorable SVS Presidential Address in 1994,
Norman Hertzer challenged the vascular surgical commu-
nity to develop mechanisms for formal outcomes assess-
JOURNAL OF VASCULAR SURGERY
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this, I would add: compared to what? – and, at what price?
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